Effects of sodium glucose cotransporter 2 inhibitors and pioglitazone on FIB-4 index in metabolic associated fatty liver disease.
Masaaki MinoEiji KakazuAkitoshi SanoHisayuki KatsuyamaMariko HakoshimaHidekatsu YanaiYoshihiko AokiMasatoshi ImamuraTaiji YamazoeTaizo MoriSachiyo YoshioJun InoueAtsushi MasamuneTatsuya KantoPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2023)
SGLT2i treatment causes a larger improvement in FIB-4 index than pioglitazone in patients with MAFLD over 96 weeks. This article is protected by copyright. All rights reserved.
Keyphrases